A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.
about
Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsTrospium chloride treatment of overactive bladderThe effects of drug and behavior therapy on urgency and voiding frequency.Bladder sensory desensitization decreases urinary urgency.Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.Changes of neuregulin-1 (NRG-1) expression in a rat model of overactive bladder induced by partial urethral obstruction: is NRG-1 a new biomarker of overactive bladder?Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.A study of bladder dysfunction in women with type 2 diabetes mellitus.A comparative study on the efficacy of solifenacin succinate in patients with urinary frequency with or without urgency.Biomarkers in overactive bladder: a new objective and noninvasive tool?Correlation between psychological stress levels and the severity of overactive bladder symptomsThe overlap and distinction of self-reported symptoms between interstitial cystitis/bladder pain syndrome and overactive bladder: a questionnaire based analysis.Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome.Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors.Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function.Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder.Lower urinary tract symptomatology: Its definition and confusion.Impact of childhood and recent traumatic events on the clinical presentation of overactive bladder.Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 studyNocturia and disturbed sleep in the elderly.Urodynamic prognostic factors for large post-void residual urine volume after intravesical injection of onabotulinumtoxinA for overactive bladder.The evaluation and treatment of nocturia: a consensus statement.Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?Potential Biomarkers Utilized to Define and Manage Overactive Bladder Syndrome.Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.Outcome Measurement of Overactive Bladder.Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity.Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder.Systemic Nonurological Symptoms in Patients with Overactive Bladder.Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome.Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial.Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.Factors associated with a better therapeutic effect of solifenacin in patients with overactive bladder syndrome.International Prostate Symptom Score for assessing lower urinary tract dysfunction in women.Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.Improving the clinical prediction of detrusor overactivity by utilizing additional symptoms and signs to overactive bladder symptoms alone.Validation of the urinary sensation scale (USS).Comparisons of the Clinical Outcomes and Urodynamic Effects of Mirabegron versus Tolterodine Treatment for Female Overactive Bladder Syndrome: A Subgroup Analysis of a Controlled, Randomised, Prospective Study.Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
P2860
Q27001248-8D1E66D8-C57B-4374-A38A-D9092F843BE7Q28308162-6318A4CB-1F9E-4E40-96BE-8B082834BF52Q30431806-3028EFF5-671A-4BBC-9884-F5438FADBB61Q30832054-78978BA2-69DB-4250-9023-B9944364BC40Q33515909-41F126BB-378B-44B0-A392-AFD414DA8F9DQ33589756-C262EC8C-30AE-4A92-B07D-A236A37021BFQ33806201-6E45C047-B661-4DF3-B445-EA6650A60DB5Q34069304-2B9F86C2-BD9C-44F8-BEE4-848F72FEDE78Q34524320-35C8F866-FC1D-46AA-8DFC-8F5AFED7B500Q35040019-573BE9C9-9CED-445B-8EF6-E2554437F7D2Q35170051-C74CFC62-9651-4C37-82C0-CE7CBB98BD1BQ35569758-3C491559-5D1F-41CC-9DDC-01F31136FC9CQ35908570-F9236A62-4D53-4336-8F39-FC2202BC32AAQ36090770-C7FCED06-894D-42BD-9F00-EC55F020C53FQ36134268-E026AC2E-310B-4780-AB33-9ED6EA3D2828Q36655193-6CB41985-F2E9-495E-B534-67E18CF84774Q37053892-66AEF93A-F6B4-456F-BEF5-9CD6D4638FE5Q37088666-24C0F431-5AC9-4551-95A7-FA809866B5D8Q37285555-0D6B6434-0C6D-4AE5-ADF8-CB6D5FB58704Q37326274-591D9927-BF42-48A2-823D-39640A0B403DQ37682186-4BEF18EE-B074-4A6A-A13F-3C4F9C518740Q37890031-8CAEC4BF-0D04-40D4-8D3E-247527AD20C4Q37919752-B98DCBDB-6536-43C1-BA3B-085AABAC4050Q37947438-F8AD200F-7AAF-4DD0-9B9D-A72CA45E8E95Q38671606-0CA30309-EBBF-4A98-9769-2F4DCC4E9394Q39268095-86013272-6415-4A5C-8535-BFA7E64C0C92Q39648989-45839E60-F796-413C-8A57-83E78C03E640Q40118662-37A13480-ECA6-495A-8638-2DFE937E229DQ40216118-20D836CB-0EDC-4836-945C-A57D2B9E88FEQ42388902-AFFC6283-213C-4A1D-AFB4-E76620E92E2EQ42671934-25CABF6B-8990-4FC4-96B0-E8137B0876DBQ43263705-E92E8FB9-FF23-4D9B-943C-2801DEADDC17Q43325794-041AAE34-F491-4E9B-A966-C4BEE76437FAQ43815698-D4444316-FEC5-44CC-A86D-7B4681E6035BQ43842651-9D7FDD28-80B9-4A34-B6AA-ED374D2CD25DQ45330381-1093549D-C131-42B6-B748-355A5626A4A7Q45856184-D4B5CB36-50D3-4B90-95B4-B43F7D7AF4C9Q46963471-478AF552-6D4C-4812-9C57-7D622F3259E3Q47784907-215A17E4-0A0C-4958-83A4-C77962A452BEQ48030799-B7FA86CC-C090-4F5D-87F6-C5E458250F82
P2860
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A validated patient reported m ...... er for use in clinical trials.
@en
A validated patient reported m ...... er for use in clinical trials.
@nl
type
label
A validated patient reported m ...... er for use in clinical trials.
@en
A validated patient reported m ...... er for use in clinical trials.
@nl
prefLabel
A validated patient reported m ...... er for use in clinical trials.
@en
A validated patient reported m ...... er for use in clinical trials.
@nl
P2093
P1476
A validated patient reported m ...... er for use in clinical trials.
@en
P2093
Annabel Nixon
Bobby Sandage
David R Staskin
Luann Sabounjian
Norman Zinner
Shoshana Colman
Ute E Schwiderski
P304
P356
10.1097/01.JU.0000165461.38088.7B
P407
P577
2005-08-01T00:00:00Z